Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
In the majority of cases of bipolar disorder, manic episodes are usually brief and typically responsive to currentlyavailable psychopharmacological agents. In contrast, depressive manifestations are more prevalent and persistent,and can present as major depressive/mixed episodes or residual interepisode symptoms. The depressive phase isoften associated with other neuropsychiatric conditions, such as anxiety spectrum disorders, substance use disorders,stressor-related disorders, and eating disorders. It is viewed as a systemic disease with associated ailmentssuch as metabolic syndrome, diabetes mellitus, and cardiovascular disease. There is an increased rate of mortalitynot only from suicide, but also from concomitant physical illness. This scenario is made worse by the fact that depressivesymptoms, which represent the main disease burden, are often refractory to existing psychotropic drugs. As such, there is a pressing need for novel agents that are efficacious in acute depressive exacerbations, and alsohave applicable value in preventing recurrent episodes. The rationale of the present review is to delineate the pharmacotherapyof the depressive phase of bipolar disorder with medications for which there is evidence in the formof observational, open-label, or double-blind randomized controlled studies. In the treatment of acute bipolar depressionin adults, a comprehensive appraisal of the extant literature reveals that among mood stabilizers, the mostrobust proof of efficacy exists for divalproex sodium; while atypical antipsychotics, which include olanzapine, quetiapine,lurasidone, and cariprazine, are also effective, as demonstrated in controlled trials.
Abstract
In the majority of cases of bipolar disorder, manic episodes are usually brief and typically responsive to currentlyavailable psychopharmacological agents. In contrast, depressive manifestations are more prevalent and persistent,and can present as major depressive/mixed episodes or residual interepisode symptoms. The depressive phase isoften associated with other neuropsychiatric conditions, such as anxiety spectrum disorders, substance use disorders,stressor-related disorders, and eating disorders. It is viewed as a systemic disease with associated ailmentssuch as metabolic syndrome, diabetes mellitus, and cardiovascular disease. There is an increased rate of mortalitynot only from suicide, but also from concomitant physical illness. This scenario is made worse by the fact that depressivesymptoms, which represent the main disease burden, are often refractory to existing psychotropic drugs. As such, there is a pressing need for novel agents that are efficacious in acute depressive exacerbations, and alsohave applicable value in preventing recurrent episodes. The rationale of the present review is to delineate the pharmacotherapyof the depressive phase of bipolar disorder with medications for which there is evidence in the formof observational, open-label, or double-blind randomized controlled studies. In the treatment of acute bipolar depressionin adults, a comprehensive appraisal of the extant literature reveals that among mood stabilizers, the mostrobust proof of efficacy exists for divalproex sodium; while atypical antipsychotics, which include olanzapine, quetiapine,lurasidone, and cariprazine, are also effective, as demonstrated in controlled trials.
참고문헌 (46)
- S. Nassir Ghaemi, "Bipolar Spectrum: A Review of the Concept and a Vision for the Future", PSYCHIATRY INVESTIGATION, 10(3), pp.218~224 (2013), 대한신경정신의학회[DOI]
- Ketter TA, "Diagnostic features, prevalence, and impact of bipolar disorder", J Clin Psychiatry, 71, pp.e14~ (2010)
- Nurnberger JI Jr, "A high-risk study of bipolar disorder: childhood clinical phenotypes as precursors of major mood disorders", Arch Gen Psychiatry, 68, pp.1012~1020 (2011)
- Krishnan KR, "Psychiatric and medical comorbidities of bipolar disorder", Psychosom Med, 67, pp.1~8 (2005)
- Sienaert P, "Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review", Bipolar Disord, 15, pp.61~69 (2013)
- Tondo L, "Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders", Acta Psychiatr Scand, 127, pp.355~364 (2013)
- Benedetti F, "Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates", J Clin Psychiatry, 66, pp.1535~1540 (2005)
- Ather Muneer, "Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers", PSYCHIATRY INVESTIGATION, 13(1), pp.18~33 (2016), 대한신경정신의학회[DOI]
- Nery LR, "Sustained behavioral effects of lithium exposure during early development in zebrafish: involvement of the Wnt-β-catenin signaling pathway", Prog Neuropsychopharmacol Biol Psychiatry, 55, pp.101~108 (2014)
- Prickaerts J, "Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania", J Neurosci, 26, pp.9022~9029 (2006)
- Watkins CC, "Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application", Transl Psychiatry, 4, pp.e350~ (2014)
- Boku S, "Valproate recovers the inhibitory effect of dexamethasone on the proliferation of the adult dentate gyrus-derived neural precursor cells via GSK-3β and β-catenin pathway", Eur J Pharmacol, 723, pp.425~430 (2014)
- Wang CC, "Valproic acid mediates the synaptic excitatory", inhibitory balance through astrocytes--a preliminary study, 2012, pp.37, 111~120
- Young AH, "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)", J Clin Psychiatry, 71, pp.150~162 (2010)
- Missio G, "The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole", Trials, 14, pp.190~ (2013)
- Lewitzka U, "Does lithium reduce acute suicidal ideation and behavior?: a protocol for a randomized, placebo-controlled multicenter trial of lithium plus Treatment As Usual (TAU) in patients with suicidal major depressive episode", BMC Psychiatry, 15, pp.117~ (2015)
- El-Mallakh RS, "A blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects", Ann Clin Psychiatry, 22, pp.3~8 (2010)
- Juruena MF, "Bipolar I and II disorder residual symptoms:oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.94~99 (2009)
- Grunze H, "Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I", J Affect Disord, 174, pp.70~82 (2015)
- Dimitrakopoulos S, "Pharmacological agents under research for the maintenance treatment in bipolar disorder", Psychiatriki, 26, pp.169~180 (2015)
- Ghaemi SN, "Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study", J Clin Psychiatry, 68, pp.1840~1844 (2007)
- Muzina DJ, "Acute efficacy of divalproex sodium versus placebo in mood stabilizernaive bipolar I or II depression: a double-blind, randomized, placebocontrolled trial", J Clin Psychiatry, 72, pp.813~819 (2011)
- Bond DJ, "Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis", J Affect Disord, 124, pp.228~234 (2010)
- Calabrese JR, "Lamotrigine in the acute treatment of bipolar depression:results of five double-blind, placebo-controlled clinical trials", Bipolar Disord, 10, pp.323~333 (2008)
- Gabriel A, "Adjunctive topiramate treatment in refractory obese bipolar patients: a descriptive open label study", Eat Weight Disord, 12, pp.48~53 (2007)
- Roy Chengappa K, "A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type", Bipolar Disord, 9, pp.609~617 (2007)
- Ankesh Kukkar, "Implications and mechanism of action of gabapentin in neuropathic pain", Archives of Pharmacal Research, 36(3), pp.237~251 (2013), 대한약학회
- Rakofsky JJ, "Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review", J Clin Psychiatry, 72, pp.81~90 (2011)
- Wang PW, "Gabapentin augmentation therapy in bipolar depression", Bipolar Disord, 4, pp.296~301 (2002)
- Schaffer LC, "An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder", J Affect Disord, 147, pp.407~410 (2013)
- Lee CY, "Levetiracetam inhibits glutamate transmission through presynaptic P", Q-type calcium channels on the granule cells of the dentate gyrus, 2009, pp.158, 1753~1762
- Saricicek A, "Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 72, pp.744~750 (2011)
- Peterson SM, "Receptor, ligand and transducer contributions to dopamine D2 receptor functional selectivity", PLoS One, 10, pp.e0141637~ (2015)
- De Bartolomeis A, "Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism", CNS Drugs, 29, pp.773~799 (2015)
- Park SM, "Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice", Neuropsychopharmacology, 41, pp.704~715 (2016)
- Macfadden W, "Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms", BMC Psychiatry, 11, pp.171~ (2011)
- Fu DJ, "Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder", J Clin Psychiatry, 76, pp.253~262 (2015)
- Tohen M, "Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies", J Affect Disord, 149, pp.196~201 (2013)
- Tohen M, "Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression", Arch Gen Psychiatry, 60, pp.1079~1088 (2003)
- Suttajit S, "Quetiapine for acute bipolar depression: a systematic review and meta-analysis", Drug Des Devel Ther, 8, pp.827~838 (2014)
- Lombardo I, "Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?", J Clin Psychopharmacol, 32, pp.470~478 (2012)
- Sachs GS, "Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 72, pp.1413~1422 (2011)
- Loebel A, "Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 171, pp.160~168 (2014)
- Loebel A, "Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 171, pp.169~177 (2014)
- Thase ME, "Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies", J Clin Psychopharmacol, 28, pp.13~20 (2008)
- Durgam S, "An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression", Am J Psychiatry, 173, pp.271~281 (2016)